Patients who were intubated and on invasive mechanical ventilation at screening were excluded, while patients with known chronic parenchymal lung disease were allowed in the study. Keywords: COVID-19; interstitial lung disease; lung fibrosis; pulmonary fibrosis EN COVID-19 interstitial lung disease lung fibrosis pulmonary fibrosis 954 957 4 09/20/23 20231001 NES 231001 DATA AVAILABILITY STATEMENT The data that support the findings of this study are available from the corresponding author upon reasonable request. Taken together, the findings of this study did not hint at any additional beneficial effect of pamrevlumab in patients with COVID-19 pneumonia as compared to SOC alone, at least not in the short term. Antifibrotic drugs have been so far investigated in chronic fibrotic disorders, and whether they could act fast enough to contrast the rapid evolution of COVID-19 pneumonia is unknown. Chronic respiratory comorbidities were infrequent in the study population, as two patients had diagnosis of chronic obstructive pulmonary disease and one patient had diagnosis of interstitial lung disease.[Extracted from the article]

Copyright of Respirology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. Copyright applies to all Abstracts.